Pay in 4 interest-free payments of $6.58 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Advances in Gerontology, 2007, Volume 20 (Issue 1), Pages 74-85
In a systematic review and meta-analysis on the safety and efficacy of DOACs and warfarin in elderly patients with atrial fibrillation, researchers concluded that there were no significant differences in the DOACs studied (rivaroxaban, dabigatran, apixaban, and edoxaban) in terms of stroke or blood clot prevention
It is not an approved medicine, and its regulatory status is under active review in several markets
Stay current on emerging research
Determining whom to treat A deficiency of B 12 may lead to a variety of symptoms
Der enthaltene Wirkstoff wird transdermal, also ber die Haut, in den Krper abgegeben
US$ 29.57
US$ 24.55
US$ 22.64
US$ 28.63
US$ 24.87
US$ 20.66
